Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
UBS Remains Sidelined on Alkermes plc (ALKS) Following Failed ALKS 5461 Studies
January 22, 2016 9:40 AM ESTUBS maintained a Neutral rating on Alkermes (NASDAQ: ALKS), and cut the price target to $36.00 (from $65.00). With the failure of FORWARD-3 and FORWARD-4 studies for ALKS 5461 in MDD, UBS believes that there is a very low possibility of getting this product approved even... More
Morgan Stanley Downgrades Alkermes (ALKS) to Underweight
January 21, 2016 12:52 PM ESTMorgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Overweight to Underweight with a price target of $35.00.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
... MoreAlkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'
January 21, 2016 10:07 AM ESTLeerink Partners analyst Paul Matteis lowered his price target on Alkermes (NASDAQ: ALKS) to $58.00 (from $84.00) after the company released news on two of its Phase 3 programs for ALKS5461 missing their primary endpoints (PEs). The firm maintained an Outperform rating.
Matteis commented, ". While the... More
Cowen Downgrades Alkermes (ALKS) to Market Perform
January 21, 2016 9:51 AM ESTCowen downgraded Alkermes (NASDAQ: ALKS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
... More